



October 31, 2023

Listing Department <b>BSE LIMITED</b> P J Towers, Dalal Street, Fort, Mumbai-400 001	<b>Code: 532321</b>	Listing Department <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai-400 051	<b>Code: ZYDUSLIFE</b>
--	---------------------	--	------------------------

Re.: **Acquisition**

Ref.: 1. **Disclosure under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated July 13, 2023**

2. **Our earlier letter of even date**

Dear Sir / Madam,

This is further to our earlier letter of even date on the captioned subject.

In the said letter, it was mentioned that the Board of Directors of Zydus Lifesciences Limited (the “**Company**” or “the **Guarantor**”) have approved entering into Sale and Purchase Agreements entering into the Sale and Purchase Agreement (“**SPA**”) amongst the Sellers (as defined in the SPA), certain individuals, the Guarantor and Zydus Pharmaceuticals UK Limited, United Kingdom (“**Zydus UK**”), a wholly owned subsidiary of the Guarantor for purchase by Zydus UK of the entire share capital of the Target Companies from the Sellers (as defined in the SPA), on terms and conditions as mentioned in the SPA.

This is to update that the parties to the SPA have executed the SPA.

Please take the above on record.

Thanking you,

Yours faithfully,

For, **Zydus Lifesciences Limited**

**Dhaval N. Soni**  
**Company Secretary**

